Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06474676 · ClinicalTrials.gov registry record · Phase 1
T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
A Phase 1 study of Metastatic Soft Tissue Sarcoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06474676 is a Phase 1 study of Metastatic Soft Tissue Sarcoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 137-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06474676, a Phase 1 study of Metastatic Soft Tissue Sarcoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To find a recommended dose of attIL2-TIL cell therapy that can be given to participant with either relapsed or metastatic sarcomas (has come back or spread to other parts of the body, respectively). To further test the dose found in Part A to see if it can help to control liposarcoma growth.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2032-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06474676
The ClinicalTrials.gov registry entry for NCT06474676 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 137-participant average among 12 other Metastatic Soft Tissue Sarcoma trials with a reported enrollment target (71% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Soft Tissue Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT06474676 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06474676 about?
NCT06474676 is a clinical study titled "T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.". To find a recommended dose of attIL2-TIL cell therapy that can be given to participant with either relapsed or metastatic sarcomas (has come back or spread to other parts of the body, respectively). To further test the dose found in Part A to see if it can help to control liposarcoma growth.
What is the current status of trial NCT06474676?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-09-29. Estimated completion is 2032-12-31.
What conditions does trial NCT06474676 study?
This clinical trial studies the following conditions: Metastatic Soft Tissue Sarcoma.
What interventions are being tested in trial NCT06474676?
The interventions under investigation include: Cyclophosphamide (DRUG), T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (DRUG).
Who is sponsoring clinical trial NCT06474676?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06474676 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
RECRUITING · Phase 1
-
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
RECRUITING · Phase 1
-
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.